KUALA LUMPUR, Feb 11 -- Sime Darby Oils (SDO) and Universiti Kebangsaan Malaysia (UKM) have announced a collaboration in the world’s first comprehensive clinical trial to determine if the palm oil derived Tocotrienols, an antioxidant in the vitamin E family, could be used as a therapeutic approach for the treatment of Non-Alcoholic Fatty Liver Disease (NAFLD).
In a filling with Bursa Malaysia today, the parties said a Memorandum of Agreement (MoA) for the collaboration, which is expected to run for two years, was signed today.
They expect to see preliminary results within six months from the commencement of the clinical trial this month and a full publication of the findings in 2021.
The MoA was signed by SDO managing director Mohd Haris Mohd Arshad and UKM Dean of Faculty of Medicine and Professor of Medicine, Professor Dr Raja Affendi Raja Ali, representing UKM’s official signatory to the MOA, Vice-Chancellor Professor Datuk Ir Dr Mohd Hamdi Bin Abd Shukor.
NAFLD is a common disorder affecting non-alcohol consumers and refers to a group of conditions involving the accumulation of excess fat in the liver, early-stage NAFLD does not usually cause any harm.
However, if untreated, it can lead to serious liver damage, including cirrhosis, a disease in which the liver does not function properly due to long-term replacement of normal liver tissues with scar tissues.
Professor Dr Raja Affendi, a consultant physician in gastroenterology and hepatology at the Hospital Canselor Tuanku Muhriz and UKM Specialist Centre, said that the prevalence of NAFLD in Malaysia could be approximately 15 to 30 per cent of the general adult population.
This projection is based on the high prevalence of other metabolic diseases in the Malaysian population that are commonly associated with NAFLD, such as high blood sugar, hypertension and obesity.
Dr Raja Affendi, who is also the lead investigator of the clinical trial, said about 60 per cent of Malaysians with slightly elevated cholesterol levels have NAFLD, and yet, no medication is available for the disease.
"We are running a randomised double-blind clinical trial with a localised demographic sample focusing on a full-spectrum testing of fatty liver, the first and most comprehensive of its kind in the world.
"At the moment it is hard to find clinical trials involving a population that has diverse racial profiles such as Malaysians," he said.
Besides, the Tocotrienols that will be used in the clinical trial studies are extracted from palm fruit (Elaeis Guineensis), earlier studies shown Tocotrienols is a powerful antioxidant and is effective in reducing arterial blockage, lowering bad cholesterols and preventing a variety of ageing-related disorders due to reduced free radicals and deoxyribonucleic acid (DNA) damage, among others.
"Tocotrienols is an antioxidant classed as a vitamin E that is unique to palm. It is 40 to 60 times more potent in antioxidative properties than the commonly known tocopherol, which is usually extracted from other vegetable oils," said Professor Dr Raja Affendi.
Meanwhile, Mohd Haris said the MOA between SDO and UKM could pave the way for more collaboration between the two organisations in the future, as well as be a catalyst for SDO to conduct further research on human health issues, in line with the company’s interest to diversify into various downstream activities and business opportunities.
He also said that currently SDO produces a Tocotrienol supplement called NATRIÉO, which has been made commercially available by the company since 2002.
"The importance of developing partnerships with institutions such as UKM is that it allows for both the development and practical implementation of our findings.
"This collaboration further solidifies our goal to be evidence-based in our claims, especially in the nutrition business. It also aligns with our aspiration to venture into the nutrition and wellness industry,” he added.
-- BERNAMA
https://bernama.com/en/business/news.php?id=1813197
Source: bernama.com